Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Biotech Hubs Are Expanding; Why GMP Complexity Is Rising Across Pharma

Emerging Biotech Hubs across North America, Europe, and Asia are attracting new pharmaceutical investments, research facilities, and global talent in 2026. While this expansion reflects strong industry growth, it also introduces new GMP Compliance challenges, validation demands, and Quality Systems
  • News
Biotech Hubs Are Expanding; Why GMP Complexity Is Rising Across Pharma

FDA Rare Disease Shift 2026; New Regulatory Risks Pharma Teams Must Track

The U.S. Food and Drug Administration (FDA) is facing growing attention over how it evaluates Rare Disease Therapies in 2026. Discussions around FDA Advisory Committees (AdComms) and patient-focused decision-making highlight a broader regulatory transformation that may reshape how pharmaceutical companies
  • News
FDA Rare Disease Shift 2026; New Regulatory Risks Pharma Teams Must Track

Good Manufacturing Practices in Malaysia in 2026: NPRA GMP Inspection Guide

Learn how Malaysia GMP guidelines and NPRA GMP inspections align with PIC/S GMP requirements. This guide explains pharmaceutical quality systems, inspection priorities, common findings, CAPA expectations, and practical strategies to improve GMP compliance and inspection readiness.
  • Blog, Quality Management System
NPRA GMP inspection in a pharmaceutical manufacturing Malaysia facility following PIC/S GMP requirements and pharmaceutical quality system standards

One Leadership Change, Hidden GMP Risks; Why Quality Systems Start to Fail

Leadership experts in the healthcare sector have warned that organizational strategies often become vulnerable during executive transitions when they rely on individual leaders instead of institutional governance. Although the discussion originated from healthcare leadership, its implications extend directly to Pharmaceutical
  • News
One Leadership Change, Hidden GMP Risks; Why Quality Systems Start to Fail

FDA Freezes CRL Transparency; What Changes for Pharma Compliance

The FDA has paused the public release of new Complete Response Letters (CRLs) while reviewing a citizen petition that challenges the legal basis of the disclosure program. The decision temporarily interrupts one of the agency’s most significant transparency initiatives and
  • News
FDA Freezes CRL Transparency; What Changes for Pharma Compliance

EMA Launches Phased Reviews; Why GMP Submission Strategies Must Change

The European Medicines Agency (EMA) has started a phased review of daraxonrasib, an investigational therapy for metastatic pancreatic cancer. However, the biggest story is not the medicine itself. Instead, the review marks one of the first real-world applications of a
  • News
EMA Launches Phased Reviews; Why GMP Submission Strategies Must Change

Pharmaceutical Warehouse in 2026: GMP Storage Requirements and Inspection Readiness

Discover how compliant pharmaceutical storage supports product quality, regulatory compliance, and inspection readiness. This guide explains warehouse controls, temperature mapping, environmental monitoring, cold chain management, and practical strategies that help reduce inspection findings while maintaining product integrity throughout the supply
  • Blog, Validation and Qualification

Regulatory Compliance Consulting in 2026: FDA, EMA, and Regulatory Affairs

Discover how pharmaceutical regulatory consulting helps organizations eliminate common GMP compliance gaps, improve FDA Compliance and EMA Compliance, implement ICH Guidelines, strengthen regulatory strategy, and achieve greater inspection readiness for successful global market authorization.
  • Blog, Quality Management System
Infographic illustrating common GMP inspection gaps, including documentation, CAPA, data integrity, change control, and risk management that support regulatory consulting services, FDA Compliance, EMA Compliance, and ICH Guidelines.

FDA Finds Gaps in Genzyme’s Data Integrity Program; Warning Letter Cites Discarded Review Records

The FDA has issued a warning letter to Sanofi’s Genzyme manufacturing facility in Waterford, Ireland, after identifying significant weaknesses in Data Integrity and quality management during an inspection. The agency found deficiencies in laboratory record reviews, traceability, and deviation handling
  • News
FDA Finds Gaps in Genzyme's Data Integrity Program; Warning Letter Cites Discarded Review Records

US Reshoring Looks Promising; GMP Validation Could Be the Real Bottleneck

New analysis suggests that pharmaceutical tariffs alone may not achieve the reshoring goals many policymakers expect. According to legal and industry experts in the United States, the economics of generic drug manufacturing, combined with GMP compliance costs and validation requirements,
  • News
US Reshoring Looks Promising; GMP Validation Could Be the Real Bottleneck